Xenon Pharmaceuticals (NASDAQ:XENE) Issues Quarterly Earnings Results, Beats Expectations By $0.05 EPS

Xenon Pharmaceuticals (NASDAQ:XENE) posted its earnings results on Thursday. The biopharmaceutical company reported ($0.84) EPS for the quarter, topping the consensus estimate of ($0.89) by $0.05, Zacks reports.

Xenon Pharmaceuticals Price Performance

Shares of XENE opened at $37.02 on Friday. Xenon Pharmaceuticals has a one year low of $33.27 and a one year high of $50.99. The firm has a market capitalization of $2.82 billion, a PE ratio of -13.13 and a beta of 1.20. The company has a 50-day simple moving average of $39.27 and a two-hundred day simple moving average of $40.30.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the company. William Blair reiterated an “outperform” rating on shares of Xenon Pharmaceuticals in a research report on Friday. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Xenon Pharmaceuticals in a research report on Tuesday, February 11th. They set a “buy” rating and a $67.00 target price for the company. HC Wainwright reissued a “buy” rating and issued a $53.00 price target on shares of Xenon Pharmaceuticals in a research note on Monday, February 24th. Finally, Needham & Company LLC restated a “buy” rating and set a $60.00 price objective on shares of Xenon Pharmaceuticals in a research report on Wednesday, November 13th. Nine equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $57.38.

Insider Buying and Selling

In other Xenon Pharmaceuticals news, CFO Sherry Aulin sold 18,709 shares of the stock in a transaction on Wednesday, December 18th. The stock was sold at an average price of $41.21, for a total transaction of $770,997.89. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Ian Mortimer sold 16,315 shares of Xenon Pharmaceuticals stock in a transaction dated Monday, January 27th. The stock was sold at an average price of $40.50, for a total value of $660,757.50. Following the completion of the sale, the chief executive officer now owns 31,302 shares of the company’s stock, valued at $1,267,731. The trade was a 34.26 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 57,492 shares of company stock valued at $2,334,969 over the last ninety days. Company insiders own 5.52% of the company’s stock.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.